These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38915767)

  • 41. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
    Benatar M; Hansen T; Rom D; Geist MA; Blaettler T; Camu W; Kuzma-Kozakiewicz M; van den Berg LH; Morales RJ; Chio A; Andersen PM; Pradat PF; Lange D; Van Damme P; Mora G; Grudniak M; Elliott M; Petri S; Olney N; Ladha S; Goyal NA; Meyer T; Hanna MG; Quinn C; Genge A; Zinman L; Jabari D; Shoesmith C; Ludolph AC; Neuwirth C; Nations S; Shefner JM; Turner MR; Wuu J; Bennett R; Dang H; Sundgreen C;
    Lancet Neurol; 2024 Jul; 23(7):687-699. PubMed ID: 38782015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enhancing clinical trials in neurodegenerative disorders: lessons from amyotrophic lateral sclerosis.
    Gladman M; Cudkowicz M; Zinman L
    Curr Opin Neurol; 2012 Dec; 25(6):735-42. PubMed ID: 23160423
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Current trends in the clinical trial landscape for amyotrophic lateral sclerosis.
    van Eijk RPA; Kliest T; van den Berg LH
    Curr Opin Neurol; 2020 Oct; 33(5):655-661. PubMed ID: 32796282
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry's Research Notification Mechanism.
    Mehta P; Raymond J; Han MK; Larson T; Berry JD; Paganoni S; Mitsumoto H; Bedlack RS; Horton DK
    J Med Internet Res; 2021 Dec; 23(12):e28021. PubMed ID: 34878988
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Human and Machine Intelligence Together Drive Drug Repurposing in Rare Diseases.
    Challa AP; Zaleski NM; Jerome RN; Lavieri RR; Shirey-Rice JK; Barnado A; Lindsell CJ; Aronoff DM; Crofford LJ; Harris RC; Alp Ikizler T; Mayer IA; Holroyd KJ; Pulley JM
    Front Genet; 2021; 12():707836. PubMed ID: 34394194
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
    Miller RG; Mitchell JD; Lyon M; Moore DH
    Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Repurposing of Guanabenz acetate by encapsulation into long-circulating nanopolymersomes for treatment of triple-negative breast cancer.
    Haggag YA; Yasser M; Tambuwala MM; El Tokhy SS; Isreb M; Donia AA
    Int J Pharm; 2021 May; 600():120532. PubMed ID: 33781877
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Integrating Transcriptomic and Structural Insights: Revealing Drug Repurposing Opportunities for Sporadic ALS.
    Sunildutt N; Ahmed F; Chethikkattuveli Salih AR; Lim JH; Choi KH
    ACS Omega; 2024 Jan; 9(3):3793-3806. PubMed ID: 38284068
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuroimmune Crosstalk Between the Peripheral and the Central Immune System in Amyotrophic Lateral Sclerosis.
    Yu W; He J; Cai X; Yu Z; Zou Z; Fan D
    Front Aging Neurosci; 2022; 14():890958. PubMed ID: 35592701
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Genetics of amyotrophic lateral sclerosis].
    Weber S; Corcia P; Viader F
    Rev Prat; 2023 Sep; 73(7):783-787. PubMed ID: 37796272
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of amyotrophic lateral sclerosis in clinical practice: Results of the expert consensus using the Delphi methodology.
    Cassereau J; Bernard E; Genestet S; Chebbah M; Le Clanche S; Verschueren A; Couratier P
    Rev Neurol (Paris); 2023 Dec; 179(10):1134-1144. PubMed ID: 37827930
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS.
    Goyal NA; Berry JD; Windebank A; Staff NP; Maragakis NJ; van den Berg LH; Genge A; Miller R; Baloh RH; Kern R; Gothelf Y; Lebovits C; Cudkowicz M
    Muscle Nerve; 2020 Aug; 62(2):156-166. PubMed ID: 31899540
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug Repurposing for Rare Diseases: A Role for Academia.
    van den Berg S; de Visser S; Leufkens HGM; Hollak CEM
    Front Pharmacol; 2021; 12():746987. PubMed ID: 34744726
    [No Abstract]   [Full Text] [Related]  

  • 54. Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases.
    Benatar M; Wuu J; McHutchison C; Postuma RB; Boeve BF; Petersen R; Ross CA; Rosen H; Arias JJ; Fradette S; McDermott MP; Shefner J; Stanislaw C; Abrahams S; Cosentino S; Andersen PM; Finkel RS; Granit V; Grignon AL; Rohrer JD; McMillan CT; Grossman M; Al-Chalabi A; Turner MR;
    Brain; 2022 Mar; 145(1):27-44. PubMed ID: 34677606
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Longitudinal comparison of the self-entry Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-RSE) and Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) as outcome measures in people with amyotrophic lateral sclerosis.
    Johnson SA; Burke KM; Scheier ZA; Keegan MA; Clark AP; Chan J; Fournier CN; Berry JD
    Muscle Nerve; 2022 Oct; 66(4):495-502. PubMed ID: 35904151
    [TBL] [Abstract][Full Text] [Related]  

  • 56. PERK modulation, with GSK2606414, Sephin1 or salubrinal, failed to produce therapeutic benefits in the SOD1G93A mouse model of ALS.
    Vieira FG; Tassinari VR; Kidd JD; Moreno A; Thompson K; Perrin S; Gill A; Hatzipetros T
    PLoS One; 2024; 19(2):e0292190. PubMed ID: 38359044
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Novel trends in orphan market drug discovery: amyotrophic lateral sclerosis as a case study.
    Clark JE; Brennan A; Ramesh TM; Heywood JA
    Front Biosci; 2002 Aug; 7():c83-96. PubMed ID: 12133810
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design.
    Oskarsson B; Maragakis N; Bedlack RS; Goyal N; Meyer JA; Genge A; Bodkin C; Maiser S; Staff N; Zinman L; Olney N; Turnbull J; Brooks BR; Klonowski E; Makhay M; Yasui S; Matsuda K
    Neurodegener Dis Manag; 2021 Dec; 11(6):431-443. PubMed ID: 34816762
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase.
    Edwards IR; Star K; Kiuru A
    Drug Saf; 2007; 30(6):515-25. PubMed ID: 17536877
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Integration of genomic variants and bioinformatic-based approach to drive drug repurposing for multiple sclerosis.
    Afief AR; Irham LM; Adikusuma W; Perwitasari DA; Brahmadhi A; Chong R
    Biochem Biophys Rep; 2022 Dec; 32():101337. PubMed ID: 36105612
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.